Ahngook Pharm said the company and CMG Pharmaceutical have signed a contract to co-promote Amortan-R Tab, a three-drug combination treatment for hypertension and dyslipidemia.

Under the agreement, Ahngook will sell Amortan-R in the domestic market. Amortan-R is a CCB-ARB-statin three-drug compound composed of amlodipine, valsartan, and rosuvastatin, released in four doses of 5/80/5mg, 5/80/10mg, 5/160/5mg, and 5/160/10mg.

ARB (Aggiotension II receptor blocker) and CCB (calcium-channel blocker) are substances used most to treat hypertension, and statin is the primary treatment for dyslipidemia. Hypertension patients have a 30 percent greater incidence of dyslipidemia than patients with normal blood pressure. Recently, interest in combining hypertension and dyslipidemia drugs has been increasing.

In particular, rosuvastatin is known to have a greater LDL-C-dropping effect compared to the same dose of other statins. Amortan-R Tab is a compound that can increase the patient's medication adherence while simultaneously controlling hypertension and dyslipidemia.

“With the signing of the co-promotion contract for Amortan-R Tab, we will continue to expand the circulatory disease treatment market by establishing various blood tension-dropping lineups, along with existing drugs such as Levotension Tab, Levomos Tab, DiQvan Tab, and CodiQvan Tab,” an Ahngook official said. “With the release of CCB/ARB/statin compound drug, we will improve the quality of life for people with hypertension accompanied by dyslipidemia.”